[1]邵 红,严 敏,陆 晔,等.慢性病性贫血患者低分子肝素治疗的临床和实验研究[J].现代检验医学杂志,2019,34(04):31-34.[doi:10.3969/j.issn.1671-7414.2019.04.008]
　SHAO Hong,YAN Min,LU Ye,et al.Clinical and Experimental Study on Low Molecular Weight Heparin in Patients with Anemia of Chronic Diseases[J].Journal of Modern Laboratory Medicine,2019,34(04):31-34.[doi:10.3969/j.issn.1671-7414.2019.04.008]
点击复制

慢性病性贫血患者低分子肝素治疗的临床和实验研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第34卷
期数:
2019年04期
页码:
31-34
栏目:
论著
出版日期:
2019-08-20

文章信息/Info

Title:
Clinical and Experimental Study on Low Molecular Weight Heparin in Patients with Anemia of Chronic Diseases
文章编号:
1671-7414(2019)04-031-04
作者:
邵 红; 严 敏; 陆 晔; 程 旭; 潘湘涛(苏州大学附属太仓医院; 江苏太仓 215400)
(苏州大学附属太仓医院,江苏太仓 215400)
Author(s):
SHAO Hong; YAN Min; LU Ye; CHENG Xu; PAN Xiang-tao
(Department of Oncology, the Taicang Hospital Affiliated to Suzhou University,Jiangsu Taicang 215400,China)
关键词:
慢性病贫血;  骨形态发生蛋白6(BMP6);  诱导铁调素(Hepcidin);  白介素6(IL-6);  血红蛋白;  低分子肝素;  治疗
分类号:
R556; R446
DOI:
10.3969/j.issn.1671-7414.2019.04.008
文献标志码:
A
摘要:
目的 研究低分子肝素(LMWH)治疗慢性病性贫血(ACD)患者前后血红蛋白(Hb)水平以及血清诱导铁调素(Hepcidin),IL-6和骨形态发生蛋白6(BMP6)的变化情况及临床意义。方法 61例ACD患者应用LMWH(4 000 u/天,共7～15天)治疗,同时应用ELISA法测定治疗前后血清Hepcidin和BMP6,应用电化学发光法测定IL-6,并分析其可能的作用机制。结果 ①61例患者治疗后Hepcidin为0.82±0.24 mg/L,低于治疗前1.05±3.83 mg/L,差异有统计学意义(t=2.5726,P<0.05),治疗后IL-6为24.88±12.58 mg/L,也明显低于治疗前38.22±31.23 mg/L,差异有统计学意义(t=2.9650,P<0.05); 而Hb和BMP6两者则无明显差异。但贫血组患者治疗后Hb水平高于治疗前(t=1.983 2,P<0.05)。②肿瘤贫血组治疗后Hb水平为91.18±15.91 g/L,高于治疗前的85.45±18.33 g/L,差异有统计学意义(t=1.971 1,P<0.05)。③肿瘤贫血组治疗后Hepcidin和IL-6分别为0.73±0.45 g/L和30.33±28.39 mg/ml,均低于治疗前的1.09±0.41 g/L和50.76±42.10 mg/ml,差异有统计学意义(分别为t=3.394 1,P<0.01和t=2.359 7,P<0.05),而BMP6差异则无统计学意义(P>0.05)。④肿瘤无贫血组各项指标差异均无统计学意义。⑤非肿瘤贫血组虽然Hb水平略有升高,但无统计学意义,其余各项指标差异均无统计学意义。⑥肿瘤组患者治疗后Hb水平与Hepcidin,IL-6均呈负相关(分别为r=-0.280 9,t=2.249 0,P<0.05和r=-0.278 1,t=2.226 6,P<0.05)。Hepcidin与IL-6呈正相关(r=0.294 1,t=2.362 2,P<0.05)。BMP6与Hb,Hepcidin和IL-6水平均无相关关系。结论LMWH可以改善患者的贫血。其可能的机制为下调IL-6和Hepcidin的表达,但与BMP6无关。
Abstract:
Objective To preliminary study the significanceof low molecular weight heparin(LMWH)in the treatment the patients of anemiaof chronic diseases(ACD),and the changes of the serum levels of BMP6,hepcidinand IL-6.Methods Used LMWH(4 000 u/day,7～15 days)to therapy 61 patients with ACD,and ELISA method was used to determine Hepcidinand BMP6 before and after treatment,and determination of IL-6 by Electrochemiluminescence,and to analyse its clinical significance.Results ①In all 61 cases,the levels of Hepcidin in post-therapy were 0.82±0.24 mg/L,which were lower than 1.05±3.83 mg/L in pretherapy(t=2.572 6,P<0.05).The levels of IL-6 in post-therapy were 24.88±12.58 mg/L,whichwere lower than 38.22±31.23 mg/L in pretherapy(t=2.965 0,P<0.05),butthere were not statistically significant both Hb and BMP6 between in pretherapyand post-therapy(all P>0.05).However,the levels of Hb in post-therapy were higher than in pretherapy(t=1.983 2,P<0.05).②After treatment,the level of Hb in tumor anemia group was 91.18±15.91 g/L,which was higherthan 85.45±18.33 g/L(t=1.971 1,P<0.05)in pretherapy.③Hepcidin and IL-6 after treatment in tumor anemia group were respectively 0.73±0.45 mg/L and 30.33±28.39 mg/ml,which were lower than 1.09±0.41 mg/L and 50.76±42.10 mg/ml respectively(t=3.394 1,P<0.01 and t=2.359 7,P<0.01)pretherapy.But BMP6 was not statistically significant(all P>0.05).④There was no statistical significance in all indexes of tumor without anemia(P>0.05).⑤The level of Hb increased slightly in the non tumor anemia group,but there was no statistical significance(P>0.05).The remaining indicators were not statistically significant(all P>0.05).⑥After treatment,thelevel of Hb was negatively correlated with Hepcidin and IL-6(respectively r=-0.280 9,t=2.249 0,P<0.05 and r=-0.278 1,t=2.226 6,P<0.05).Hepcidin was positive related to IL-6(r=-0.294 1,t=2.362 2,P<0.05).There was no correlation between BMP6 and Hb, Hepcidin and IL-6 levels.Conclusion LMWH could up-regulate the levels of Hb,and better for the degree of anemia in patients with ACD.The possible mechanism is to reduce the level of Hepcidin and IL-6.

参考文献/References:

[1] 潘湘涛,陆晔,程旭,等.癌性患者血清hepcidin及炎症介质细胞因子表达特点及其与贫血的关系[J].现代检验医学杂志,2011,26(4):22-24,27. PAN Xiangtao,LU Ye,CHENG Xu,et al.Expression characters of serumhepcidin,inflammatory mdiators and cytokines in patients with cancer and the relations between anemia and them[J].J Mod Lab Med.2016,26(4):22-24,27. [2] ZHANG Ansheng,YANG Fan,WANG Junming,et al.Hemojuvelin-neogenin interaction is required for bone morphogenic protein-4-induced hepcidin expression[J].J Biol Chem,2009,284(34):22580-22589. [3] NEMETH E.Targeting the hepcidin-ferroportin axis in the diagnosis and treatment of anemia[J].Adv Hemarol,2010(2),750643. [4] 严敏,程旭,陆晔,等.肿瘤患者不同C反应蛋白水平与IL-6及贫血的关系[J].中国继续医学教育,2018,10(34):76-78. YAN Min,CHENG Xu,LU Ye,et al.The relationship of expression levels of C-reactive protein with serum IL-6 and anemia in tumor patients[J].China Continuing Medical Education,2018,10(34):76-78. [5] AKCHURIN O,SURESHBABU A,DOTY S B,et al.Lack of hepcidn ameliorates anemia and improves growth in an adenine-induced mouse model of chronic kidney disease[J].Am J Physiol Renal Physiol,2016,311(5):F877-F889. [6] NAIRZ M,THEURL I,WOLF D,et al.Iron deficiency or anemia of inflammation?:differential diagnosis and mechanisn of anemian of inflammation[J].WiebMed Wochenschr,2016,166(13/14):411-423. [7] POLI M,ASPERTI M,RUZZENENTI P,et al.Hepcidin antagonists for potential treatments of disorders with hepcidin excess[J].Front Pharmacol,2014,5:86. [8] POLI M,GIRELLI D,CAMPOSTRINI N,et al.Heparin:A potent inhibitor of hepcidin expression in vitro and in vivo[J].Blood,2016,117(3):997-1004. [9] 陆晔,邵红,程旭,等.低分子肝素对慢性病贫血患者Hb和C反应蛋白水平影响的初步研究[J].现代检验医学杂志,2019,34(1):130-132. LU Ye,SHAO Hong,CHENG Xu,et al.Preliminary study on the effectsof low molecular weight heparin on Hb and C reactive protein levels in patints with chronic anemia[J].J Mod Lab Med,2019,34(1):130-132.

备注/Memo

备注/Memo:
作者简介:邵 红(1982-),女,硕士,主治医师,主要从事肿瘤的基础与临床研究工作。 通讯作者:潘湘涛(1963-),男,博士,主任医师,主要从事肿瘤的基础与临床研究工作,E-mail:panxiangtao@csco.ac.cn。收稿日期:2019-04-23 修回日期:2019-04-29
更新日期/Last Update: 2019-07-30